Pharmaceutical IP Enforcement
Novo vs. Hims Isn’t About Weight-Loss Drugs — It’s About When “Stopping” Stops Mattering
Novo Nordisk’s lawsuit against Hims after a GLP-1 alternative was withdrawn signals that in regulated markets, demonstrating substitute capability can trigger enforcement even when sales stop.